KPTICongressional Stock Trades
Karyopharm Therapeutics Inc.
Pharmaceutical Preparations
Congressional stock trades in Karyopharm Therapeutics Inc. (KPTI) from House and Senate STOCK Act filings. See which members of Congress bought or sold, disclosed amounts, and filing dates.
Total Trades
1
Politicians Trading
1
Last Traded
Feb 20, 2025
Trading History
| Politician | Notified | Traded | Type | Amount | Change |
|---|---|---|---|---|---|
| Ashley MoodyR | Mar 22, 2025 | Feb 20, 2025 | Sell | $1,001 - $15,000 | -98.78% |
Price History
About Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).
1 members of Congress have disclosed 1 trades in Karyopharm Therapeutics Inc. (KPTI). Most active: Ashley Moody (1).
Across all disclosures, members of Congress reported 0 purchases and 1 sales of Karyopharm Therapeutics Inc. (KPTI). The most recent trade was on Feb 20, 2025.
Ashley Moody disclosed selling Karyopharm Therapeutics Inc. (KPTI) on Feb 20, 2025, valued at $1,001 - $15,000.
From House and Senate periodic transaction reports filed under the STOCK Act. Members of Congress must disclose trades within 45 days, and amounts are reported as ranges, not exact values.